Shield Therapeutics PLC Investor presentation
21 Septiembre 2021 - 01:00AM
RNS Non-Regulatory
TIDMSTX
Shield Therapeutics PLC
21 September 2021
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Investor presentation
Hardman & Co Life Sciences Investor Forum
London, UK, 21 September, 2021: Shield Therapeutics plc (LSE:
STX), a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product
Feraccru(R)/Accrufer(R) (ferric maltol), announces Greg Madison,
CEO of Shield, will be presenting at the Hardman & Co Life
Sciences Investor Forum on Thursday 23 September 2021.
The webinar event will begin at 17:00 (BST) and investors can
register to attend here:
https://hardman-co.com/p/49CL-HU2/join-our-webinar
No new material information will be disclosed at this event and
the presentation will be made available on the Company website
shortly after the event.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Alice Lane/George
Dollemore +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
Paul McManus/Lianne Cawthorne
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product
Feraccru(R)/Accrufer(R) (ferric maltol), a novel, stable, non-salt
based oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK,
Switzerland and Australia and has exclusive IP rights until the
mid-2030s. Accrufer(R) has been launched in the US in July 2021
through a highly experienced sales and marketing team. Feraccru(R)
is already being commercialised in the UK and European Union by
Norgine B.V., who also have the marketing rights in Australia and
New Zealand. Shield also has an exclusive licence agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong,
Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com.
Follow Shield on Twitter @ShieldTx
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRALMMITMTATBBB
(END) Dow Jones Newswires
September 21, 2021 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024